Donor consent frameworks for cells used in bioprinting

Introduction

Bioprinting is an emerging biotechnology that uses living cells, biomaterials and specialised printing technologies to create tissue-like structures for research, medical testing and potential transplantation. Human cells used in bioprinting may come from blood, skin, bone marrow, surgical tissues, umbilical cord blood or other biological materials.

The collection and use of these cells raise important legal and ethical questions concerning informed consent, privacy, ownership, commercialisation and future research. Donors must understand how their biological materials will be collected, stored, processed and used. A consent obtained only for medical treatment may not automatically authorise the use of cells for commercial bioprinting or unrelated research.

Legal framework in India

India does not yet have a comprehensive statute specifically regulating donor consent for cells used in bioprinting. However, several existing legal frameworks are relevant.

1. Indian Council of Medical Research guidelines

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 establish important standards for informed consent and ethical research. They require researchers to explain the purpose of research, procedures, foreseeable risks, benefits, confidentiality arrangements and the voluntary nature of participation.

Where biological materials are collected for future research, the consent process should explain the proposed uses, storage arrangements and possibilities of future research, including whether commercial applications are anticipated.

2. New Drugs and Clinical Trials Rules, 2019

These Rules regulate clinical trials and certain biomedical research activities involving new drugs and investigational products. Where bioprinted tissues or related products fall within their regulatory scope, appropriate ethics committee review and informed consent requirements become relevant.

3. Transplantation of Human Organs and Tissues Act, 1994

The Act regulates the removal, storage and transplantation of specified human organs and tissues. Its applicability depends on the nature and intended use of the biological material. It should not be assumed that every cell sample used in laboratory bioprinting automatically falls within its provisions.

4. Digital Personal Data Protection Act, 2023

Genetic information and identifiable medical information associated with donated cells may constitute personal data. Their processing must comply with applicable data-protection requirements, including lawful processing, security and relevant consent obligations, subject to the Act's commencement and applicable rules.

Essential elements of donor consent

A legally and ethically appropriate consent framework should address the complete lifecycle of donated cells.

Purpose of collection: Donors should understand whether cells are collected for treatment, laboratory research, tissue engineering, transplantation or commercial product development.

Nature of procedures: Information should cover collection methods, foreseeable risks and possible discomfort.

Storage and preservation: Consent should explain how long cells may be stored, where they will be kept and who may access them.

Future research: Researchers should specify whether samples may be used in future studies and whether additional consent will be required.

Commercial use: Donors should be informed if their cells may contribute to commercially developed bioprinted products.

Privacy protection: Genetic and health information should be protected through access restrictions, secure storage and appropriate anonymisation or pseudonymisation.

Withdrawal rights: Donors should be informed about the limits of withdrawing consent after cells have been processed, distributed or incorporated into research products.

Consent should be voluntary, understandable and documented. Special safeguards are necessary when biological materials are obtained from children or individuals who cannot independently provide informed consent.

Important judicial decisions and case laws

1. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court held that valid medical consent must be voluntary and based on adequate information about the nature and purpose of the proposed procedure, its risks and available alternatives.

Legal significance: The decision supports the requirement that donors receive clear information before their cells are collected and used for bioprinting. Consent for one purpose should not automatically be treated as consent for an unrelated purpose.

2. K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms. Informational privacy includes protection against unjustified collection and use of personal information.

Legal significance: Genetic information linked to donated cells requires strong privacy safeguards. Bioprinting institutions must consider confidentiality, data security and appropriate control over personal information.

3. Common Cause v. Union of India (2018)

The Supreme Court recognised the importance of individual autonomy and dignity in medical decision-making, particularly in relation to end-of-life care and advance directives.

Legal significance: Although not a bioprinting case, its recognition of personal autonomy supports the principle that individuals should retain meaningful control over decisions concerning their bodies and medical interests.

4. Sharda v. Dharmpal (2003)

The Supreme Court considered medical examination in matrimonial proceedings and explained that bodily autonomy must be balanced against legal requirements in appropriate circumstances.

Legal significance: The judgment is relevant by analogy when examining the legal limits of bodily autonomy and the circumstances in which medical interventions or examinations may be authorised.

5. Aruna Ramachandra Shanbaug v. Union of India (2011)

The Supreme Court examined medical decision-making, dignity and the role of consent and safeguards in serious healthcare situations.

Legal significance: The judgment contributes to the broader understanding of autonomy and protection of vulnerable individuals, principles that are relevant when designing consent procedures for donors who may have limited decision-making capacity.

These decisions do not directly determine ownership or consent rules for bioprinted cells. They provide constitutional and medical-consent principles that can guide future regulation.

Challenges and regulatory safeguards

Donor consent becomes complicated when cells are modified, multiplied, genetically altered or combined with synthetic biomaterials. A sample initially collected for research may later contribute to a commercially valuable tissue product. This creates questions about the scope of original consent, donor expectations and possible financial interests.

Institutions should adopt standard consent forms, independent ethics committee review, clear commercial-use disclosures, secure biological sample registers and procedures for handling withdrawal requests. Separate consent categories for clinical treatment, research and commercial development can improve transparency.

Conclusion

Donor consent is a fundamental requirement for the ethical and lawful use of human cells in bioprinting. Indian constitutional principles, medical-consent jurisprudence and biomedical research guidelines provide a foundation for regulating this emerging field. However, specific legislation addressing cell ownership, commercialisation, long-term storage and withdrawal of consent remains necessary. A comprehensive framework should protect donor autonomy while allowing responsible scientific innovation and the development of regenerative medicine.